The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.

[1]  B. Gansbacher,et al.  Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. , 1994, Journal of immunology.

[2]  Lieping Chen,et al.  Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. , 1994, Journal of immunology.

[3]  M. Colombo,et al.  Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? , 1994, Immunology today.

[4]  R. Furth,et al.  Increased adhesion of human monocytes to IL‐4‐stimulated human venous endothelial cells via CD11/CD18, and very late antigen‐4 (VLA‐4)/vascular cell adhesion molecule‐1 (VCAM‐Independent mechanisms , 1993, Clinical and experimental immunology.

[5]  K. Maclennan,et al.  Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour. , 1993, British Journal of Cancer.

[6]  G. Freeman,et al.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Gilboa,et al.  Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. , 1993, Journal of immunology.

[9]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[10]  A. Porgador,et al.  Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. , 1992, Cancer research.

[11]  F. Farzaneh,et al.  Construction of a versatile set of retroviral vectors conferring hygromycin resistance. , 1992, BioTechniques.

[12]  T. Honjo,et al.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[14]  K. Tracey,et al.  Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Volk,et al.  Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer , 1991, The Journal of experimental medicine.

[16]  M. Colombo,et al.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo , 1991, The Journal of experimental medicine.

[17]  P. Kourilsky,et al.  Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivo , 1991, European journal of immunology.

[18]  S. Eccles,et al.  Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL‐2 cDNA , 1991, International journal of cancer.

[19]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[20]  T. Blankenstein,et al.  Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. , 1990, Molecular immunology.

[21]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[22]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[23]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[24]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[26]  S. Goff,et al.  Construction and use of a safe and efficient amphotropic packaging cell line. , 1988, Virology.

[27]  C. Sugiura,et al.  XENOGENIZATION OF TUMOR CELLS BY TRANSFECTION WITH PLASMID CONTAINING env GENE OF FRIEND LEUKEMIA VIRUS , 1988, Japanese journal of cancer research : Gann.

[28]  B. Vogelstein,et al.  Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. , 1988, Cancer research.

[29]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[30]  S. Segal,et al.  Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection , 1985, Nature.

[31]  H. Hewitt,et al.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. , 1976, British Journal of Cancer.

[32]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.